Loading…
Indo Us Biotech (INDOUS)₹66.55−1.60%Other Agricultural Products
In the Mar 2026 quarter (standalone), Indo Us Biotech reported sales of ₹26.01 Cr, down 22.0% from Mar 2025, and net profit of ₹1.96 Cr, down 46.9% year on year. For the year to Mar 2026, sales were ₹110 Cr and net profit ₹12.99 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.12 | 15.80 | 22.10 | 15.76 | 24.71 | 22.16 | 23.55 | 33.34 | 30.76 | 30.81 | 22.78 | 26.01 |
| Expenses | 16.18 | 13.23 | 17.92 | 14.82 | 21.06 | 17.08 | 18.05 | 28.84 | 25.37 | 26.76 | 18.67 | 22.85 |
| Operating Profit | 2.98 | 2.59 | 4.22 | 0.97 | 3.68 | 5.11 | 5.53 | 4.57 | 5.46 | 4.15 | 4.14 | 3.22 |
| OPM % | 15.6% | 16.4% | 19.1% | 6.2% | 14.9% | 23.0% | 23.4% | 13.7% | 17.7% | 13.5% | 18.1% | 12.4% |
| Other Income | 0.02 | 0.00 | 0.07 | 0.20 | 0.02 | 0.01 | 0.01 | 0.11 | 0.00 | 0.02 | 0.00 | 0.01 |
| Interest | 0.36 | 0.40 | 0.36 | 0.35 | 0.32 | 0.51 | 0.37 | 0.25 | 0.44 | 0.41 | 0.76 | 0.59 |
| Depreciation | 0.19 | 0.20 | 0.18 | 0.19 | 0.19 | 0.17 | 0.15 | 0.55 | 0.19 | 0.20 | 0.21 | 0.26 |
| Profit before tax | 2.46 | 1.99 | 3.77 | 0.64 | 3.20 | 4.46 | 5.04 | 3.89 | 4.84 | 3.57 | 3.18 | 2.39 |
| Tax % | 3.3% | 15.6% | 1.9% | 17.5% | 0.6% | 2.0% | −0.8% | 4.9% | 2.5% | 3.1% | 5.4% | 17.2% |
| Net Profit | 2.38 | 1.66 | 3.69 | 0.53 | 3.18 | 4.37 | 5.06 | 3.69 | 4.71 | 3.46 | 3.01 | 1.96 |
| EPS (Rs) | 1.17 | 0.82 | 1.83 | 0.25 | 1.57 | 2.16 | 2.51 | 1.83 | 2.33 | 1.71 | 1.49 | 0.97 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.99 | 23.99 | 29.01 | 35.01 | 39.97 | 39.01 | 48.98 | 61.01 | 72.98 | 104 | 110 | 110 |
| Expenses | 19.04 | 23.05 | 27.04 | 32.06 | 36.06 | 34.09 | 42.06 | 51.12 | 62.13 | 85.13 | 93.24 | 93.65 |
| Operating Profit | 0.00 | 0.99 | 2.99 | 2.99 | 3.99 | 5.99 | 6.99 | 8.98 | 10.98 | 18.95 | 16.98 | 16.97 |
| OPM % | 2.6% | 5.0% | 9.0% | 10.0% | 10.0% | 13.9% | 14.0% | 15.0% | 14.9% | 18.0% | 15.0% | 15.4% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Interest | 0.00 | 0.99 | 0.99 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 2.20 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.86 |
| Profit before tax | 0.00 | 1.01 | 2.01 | 3.01 | 3.01 | 4.02 | 5.02 | 7.02 | 9.03 | 17.06 | 14.05 | 13.98 |
| Tax % | −50.0% | 25.0% | 29.0% | 26.0% | 12.0% | −23.0% | 5.0% | 2.0% | 6.0% | 2.0% | 6.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | −0.02 | −0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.00 | 1.01 | 1.99 | 3.01 | 4.99 | 5.01 | 7.01 | 8.01 | 16.01 | 12.99 | 13.14 |
| EPS (Rs) | 0.79 | 0.88 | 1.40 | 1.43 | 1.73 | 3.51 | 2.85 | 3.59 | 4.09 | 8.07 | 6.52 | 6.50 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.00 | 1.01 | 1.01 | 3.01 | 5.01 | 6.01 | 6.01 | 9.02 | 10.02 | 20.05 | 20.05 | 20.05 |
| Reserves | 0.99 | 1.99 | 1.99 | 1.99 | 8.97 | 9.96 | 14.95 | 29.91 | 43.85 | 42.88 | 57.84 | 71.87 |
| Borrowings | 2.00 | 5.01 | 5.01 | 7.01 | 6.01 | 9.01 | 11.02 | 12.02 | 12.03 | 14.02 | 15.03 | 37.07 |
| Other Liabilities | 2.99 | 5.99 | 3.99 | 5.97 | 3.97 | 9.97 | 10.98 | 3.99 | 3.02 | 7.04 | 4.02 | 4.02 |
| Total Liabilities | 7.98 | 14.00 | 13.00 | 16.98 | 23.96 | 34.95 | 43.96 | 55.94 | 68.92 | 83.99 | 97.94 | 133 |
| Fixed Assets | 0.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 5.99 | 6.98 | 6.99 | 9.98 | 10.97 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 1.99 | 1.99 | 0.99 | 3.99 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 6.99 | 13.01 | 11.01 | 15.99 | 20.98 | 31.97 | 38.98 | 47.96 | 60.95 | 74.01 | 87.96 | 121 |
| Inventories | 3.99 | 4.99 | 4.99 | 5.99 | 10.97 | 8.99 | 11.99 | 22.95 | 26.97 | 51.90 | 70.89 | 98.81 |
| Trade receivables | 1.01 | 6.02 | 5.02 | 9.04 | 9.03 | 21.07 | 25.11 | 21.08 | 25.10 | 19.07 | 15.06 | 14.05 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 6.01 |
| Total Assets | 7.98 | 14.00 | 13.00 | 16.98 | 23.96 | 34.95 | 43.96 | 55.94 | 68.92 | 83.99 | 97.94 | 133 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | −1.01 | −3.01 | −1.01 | 0.00 | 3.01 | 1.01 | 2.01 | 1.01 | −13.03 |
| Cash from investing activity | — | 0.00 | −2.99 | −0.99 | −1.99 | −4.99 | −6.99 | −2.99 | −0.99 | −1.99 |
| Cash from financing activity | — | 1.01 | 6.01 | 1.99 | 1.01 | 2.01 | 6.01 | 1.01 | −0.99 | 19.99 |
| Net cash flow | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | −0.99 | 5.98 |
| Capex | 0.16 | 0.44 | 1.28 | 0.39 | 1.90 | 3.96 | 1.81 | 2.60 | 0.85 | 2.40 |
| Free cash flow | — | −0.99 | −3.99 | −0.99 | −1.99 | −0.99 | −0.99 | 0.00 | 0.99 | −14.98 |
| CFO / OP % | — | −15.9% | −91.9% | −19.9% | 6.0% | 47.1% | 9.1% | 23.1% | 9.1% | −70.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 26 | 108 | 77 | 113 | 95 | 194 | 230 | 153 | 149 | 96 | 54 | 46 |
| Inventory days | 92 | 119 | 93 | 99 | 177 | 752 | — | — | — | — | — | — |
| Days payable | 57 | 115 | 64 | 71 | 34 | 667 | — | — | — | — | — | — |
| Cash conversion cycle | 59 | 110 | 104 | 138 | 236 | 276 | 229 | 152 | 148 | 95 | 53 | 45 |
| Working capital days | 65 | 32 | 33 | 58 | 128 | 136 | 185 | 256 | 284 | 265 | 246 | 247 |
| ROCE % | 14.0% | 7.0% | 14.0% | 28.0% | 20.0% | 17.0% | 18.0% | 16.0% | 15.0% | 14.0% | 21.0% | 14.0% |
For the Mar 2026 quarter, Indo Us Biotech reported sales of ₹26.01 Cr, down 22.0% year on year and net profit of ₹1.96 Cr, down 46.9% year on year. The operating margin was 12.4%.
Indo Us Biotech's sales for the year to Mar 2026 were ₹110 Cr; over the last twelve months they were ₹110 Cr.
Net profit for the year to Mar 2026 was ₹12.99 Cr, and ₹13.14 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.50.
Indo Us Biotech reported borrowings of ₹37.07 Cr at Mar 2026, against cash and equivalents of ₹6.01 Cr.
Cash from operations was −₹13.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹14.98 Cr.